Clinical trial · Observational
Retrospective Study of Long-Term Survival of "Immuncell-LC" in Patients Undergoing Curative Resection for HCC in Korea
A Multicenter, Retrospective Data Analysis Study on the Long-term Survival Rate of the 'Immuncell-LC Goups' and 'Non-treatment Groups' in Patient Undergo Curative Resection (PEIT, RFA or Operation) for Hepatocellular Carcinoma in Korea
NCT06620510CI-TRIAL-00093681completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
To observation that long term follow-up study of 'Immuncell-LC groups' and 'Non-treatment groups' in patient undergo curative resection (PEIT, RFA or Operation) for hepatocellular carcinoma in Korea
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Hepatocellular Carcinoma | Hepatocellular Carcinoma | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Immuncell-LC | Biological | — | UNRESOLVED |
| No Interventions | Biological | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- No intervention
- description
- Patients who were in non-treatment group in phase 3 clinical trial IIC-I01(NCT00699816).
- interventionNames
- Biological: No Interventions
- label
- Immuncell-LC Group
- description
- Patients who were in Immuncell-LC group in phase 3 clinical trial IIC-I01(NCT00699816).
- interventionNames
- Biological: Immuncell-LC
Primary outcomes (1)
- measure
- Recurrence-free Survival(RFS)
- timeFrame
- up to 9 years
- description
- RFS was measured from the date of randomization to the first recurrence or to death from any cause. Radiological test should be operated by dynamic CT, dynamic MRI or by angiography.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 75 Years
Show eligibility criteria text
Inclusion Criteria: * Patients of participated in the(ClinicalTrials.gov Identifier:NCT00699816)clinical trial. Exclusion Criteria: * NA
References
Publications (0)
Data not yet available
No reference posted for this study.